Pricing Log in Create free account
Saturday 17 October 2026 Export BNR’s income statement to Excel — free account

Burning Rock Biotech Limited Sponsored ADR

BNR Healthcare Diagnostics & Research

Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024. In the quarter to June 2026, revenue fell 4.22%, EPS fell 98.4%, free cash flow grew 46.0% and total debt fell 5.02%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

12.69 2.91 −18.65%
Market cap
$137.1M
P/E
0.0×
Fwd P/E
11.1×
Dividend yield
—
F-score
5/9
Altman Z
−2.95
Beneish M
−2.47
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Burning Rock Biotech Limited Sponsored ADR (BNR) Business Profile

Updated before January 2025

Company Overview

Burning Rock Biotech Limited Sponsored ADR (BNR) is a leading biotechnology company specializing in next-generation sequencing (NGS)-based cancer diagnostics. Founded in 2014 and headquartered in Guangzhou, China, the company has established itself as a pioneer in precision oncology. BNR was founded by Yusheng Han, who also serves as the CEO, and has since grown into a globally recognized player in the field of cancer diagnostics. The company went public in June 2020, listing its American Depositary Receipts (ADRs) on the NASDAQ stock exchange under the ticker symbol “BNR.”

The leadership team at Burning Rock Biotech includes a group of seasoned professionals with extensive experience in biotechnology, genomics, and healthcare. Yusheng Han, the founder and CEO, has been instrumental in driving the company’s vision of leveraging cutting-edge technology to improve cancer treatment outcomes. The company’s board of directors and executive team bring a wealth of expertise in research, development, and commercialization, ensuring a strong foundation for sustained growth.

Core Business Segments

Burning Rock Biotech operates across several core business segments, each focused on advancing cancer diagnostics and treatment through innovative technologies. These segments include:

1. Early Cancer Detection

BNR is at the forefront of developing NGS-based solutions for early cancer detection. The company’s flagship product in this category is its “OverC” multi-cancer detection test, which uses liquid biopsy technology to identify cancer at its earliest stages. This test is designed to detect multiple types of cancer through a simple blood draw, offering a non-invasive and highly accurate diagnostic solution.

2. Companion Diagnostics

The company collaborates with pharmaceutical companies to develop companion diagnostic tests that help identify patients who are most likely to benefit from specific targeted therapies. These tests are critical for personalized medicine, enabling oncologists to tailor treatments based on the genetic profile of a patient’s tumor.

3. Clinical Testing Services

BNR provides a range of clinical testing services to hospitals, research institutions, and pharmaceutical companies. These services include tumor profiling, genetic testing, and biomarker analysis, all aimed at improving cancer diagnosis and treatment planning.

4. Research and Development (R&D) Solutions

Burning Rock Biotech also offers R&D solutions to support drug development and clinical trials. These services include genomic data analysis, biomarker discovery, and custom assay development, helping pharmaceutical companies accelerate the development of new cancer therapies.

Business Model

Burning Rock Biotech’s business model is centered around integrating its products and services to create a comprehensive ecosystem for cancer diagnostics and treatment. The company generates revenue through the sale of diagnostic tests, clinical testing services, and R&D solutions. Additionally, BNR collaborates with pharmaceutical companies to develop companion diagnostics, creating a mutually beneficial partnership that drives innovation and revenue growth.

The company’s approach to business is heavily focused on research and development, with a significant portion of its resources allocated to advancing its NGS technology and expanding its product portfolio. By combining cutting-edge technology with a deep understanding of oncology, BNR aims to provide solutions that address unmet medical needs and improve patient outcomes.

Strategic Direction

Burning Rock Biotech has outlined a clear strategic direction aimed at driving growth and innovation in the field of cancer diagnostics. Key elements of the company’s strategy include:

1. Expanding Product Portfolio

BNR is committed to expanding its product portfolio to include new diagnostic tests and services. The company is actively investing in R&D to develop next-generation solutions for early cancer detection, tumor profiling, and personalized medicine.

2. Global Expansion

Recognizing the growing demand for precision oncology solutions, BNR is focused on expanding its presence in international markets. The company is exploring partnerships and collaborations to establish a global footprint and reach more patients worldwide.

3. Sustainability Goals

As part of its commitment to sustainability, Burning Rock Biotech is working to minimize its environmental impact by adopting eco-friendly practices in its operations and supply chain. The company is also investing in initiatives that promote social responsibility and community engagement.

4. Innovation in Liquid Biopsy Technology

BNR is dedicated to advancing liquid biopsy technology, which has the potential to revolutionize cancer diagnostics. The company is exploring new applications for this technology, including monitoring treatment response and detecting minimal residual disease.

Competitive Landscape

Burning Rock Biotech operates in a highly competitive industry, facing competition from both established players and emerging startups. Key competitors include:

  • Guardant Health: A leader in liquid biopsy technology, offering a range of NGS-based cancer diagnostics.
  • Foundation Medicine: Known for its comprehensive genomic profiling solutions for cancer patients.
  • Illumina: A global leader in NGS technology, providing platforms and solutions for genomic analysis.
  • Freenome: A biotechnology company focused on early cancer detection using machine learning and genomics.
  • Exact Sciences: Specializes in cancer screening and diagnostic tests, including the widely known Cologuard test.

Despite the competitive landscape, BNR differentiates itself through its focus on the Chinese market, strong R&D capabilities, and strategic partnerships with pharmaceutical companies.

Risk Factors

Burning Rock Biotech faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Market Dependence: The company’s revenue is heavily dependent on the adoption of its diagnostic tests and services. Any decline in demand could adversely affect its financial performance.
  • Regulatory Challenges: Operating in the healthcare industry, BNR is subject to stringent regulatory requirements. Delays or failures in obtaining regulatory approvals could hinder product launches and market expansion.
  • Supply Chain Disruptions: The company relies on a global supply chain for the production of its diagnostic tests. Disruptions in the supply chain, such as shortages of raw materials or logistical challenges, could impact its operations.
  • Competition: Intense competition from other biotechnology companies could limit BNR’s market share and profitability.
  • Economic and Geopolitical Factors: Global economic conditions and geopolitical tensions could affect the company’s operations and growth prospects.

Recent Developments

Burning Rock Biotech has made significant strides in recent years, with several notable developments:

  • Launch of OverC Multi-Cancer Detection Test: The company recently launched its OverC test, which has received positive feedback for its accuracy and ease of use.
  • Partnerships with Pharmaceutical Companies: BNR has entered into strategic partnerships with leading pharmaceutical companies to develop companion diagnostics and support drug development.
  • Expansion into International Markets: The company has made progress in expanding its presence in global markets, including the United States and Europe.
  • Advancements in Liquid Biopsy Technology: BNR continues to invest in liquid biopsy research, exploring new applications and improving the performance of its diagnostic tests.

Investment Considerations

Investors considering Burning Rock Biotech as a potential investment should weigh the following strengths and risks:

Strengths

  • Strong focus on innovation and R&D.
  • Leadership position in the Chinese cancer diagnostics market.
  • Growing demand for precision oncology solutions.
  • Strategic partnerships with pharmaceutical companies.
  • Expanding product portfolio and global presence.

Risks

  • Dependence on a limited number of products and services.
  • Regulatory and compliance challenges.
  • Intense competition in the biotechnology industry.
  • Vulnerability to economic and geopolitical factors.

Conclusion

Burning Rock Biotech Limited Sponsored ADR (BNR) is a dynamic and innovative player in the field of cancer diagnostics. With a strong focus on next-generation sequencing technology, the company is well-positioned to capitalize on the growing demand for precision oncology solutions. While the company faces challenges such as competition and regulatory hurdles, its commitment to innovation, strategic partnerships, and global expansion provide a solid foundation for future growth. As BNR continues to advance its product portfolio and expand its market presence, it remains a compelling investment opportunity for those seeking exposure to the biotechnology sector.